DOAC News
DOAC Dataform and Dictionary Updated 09/12/2025
Submitted by admin on Fri, 2025-09-12 13:11DOAC Dataform Updated 08/20/2024
Submitted by admin on Thu, 2024-08-22 17:23The data form document has been updated. We have added specific questions regarding hematuria adverse events in the follow-up form. Download it here.
DOSE Protocol updates posted 08/02/2024
Submitted by admin on Wed, 2024-08-07 17:04DOSE Protocol updates posted 02/16/2024
Submitted by admin on Mon, 2024-02-19 13:11The document was revised, for dabigatran (all Indications) and rivaroxaban (all Indications except CAD & PAD) to add the following statement: “Consider alternative anticoagulation in patients who develop significant acute renal failure”
DOSE Protocol updates posted 01/27/2024
Submitted by admin on Mon, 2024-01-29 11:10Page 3 of the document has been revised, for all DOACs, with the following “Not recommended as first-line therapy in patients with antiphospholipid antibody syndrome (APS)”.
DOSE Protocol updates posted 01/08/2024
Submitted by shensky on Mon, 2024-01-08 18:01DOSE protocol document was revised on 01/08/2024 - includes minor typo corrections.
DOSE Protocol updates posted 11/01/2023
Submitted by shensky on Tue, 2023-11-07 14:24DOSE protocol document was revised on 11/01/2023 - a reintroduction of posaconazole to the DOSE alerts.
DOSE Protocol updates posted 07/25/2023
Submitted by shensky on Tue, 2023-08-01 12:28DOSE protocol document was revised on 7/25/2023 - an update regarding use of Rivaroxaban.
Data Dictionary Updated 05/03/2023
Submitted by admin on Tue, 2023-05-09 13:52The data dictionary has been updated. The form has been revised to clarify Section 5 Medications. Download it here.
